Form 4: Sutro Biopharma Executive Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
David Pauling, Chief Administrative Officer & General Counsel of Sutro Biopharma, acquired stock options and restricted stock units (RSUs) according to a Form 4 filing.
Summary
- David Pauling, Chief Administrative Officer & General Counsel of Sutro Biopharma, filed a Form 4 with the SEC.
- The filing reports the acquisition of stock options and restricted stock units (RSUs).
- Pauling acquired options to buy 101,500 shares of common stock at an exercise price of $0.55 per share, vesting monthly from May 4, 2025, and fully vested by April 4, 2029.
- He also acquired 94,250 RSUs, which represent a contingent right to receive one share of Sutro Biopharma's common stock upon settlement, vesting annually from March 2, 2026.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The grant of stock options and RSUs to a key executive is a standard practice and indicates confidence in the company's future. The vesting schedule promotes long-term commitment.
Positives
- The acquisition of stock options and RSUs by a key executive signals confidence in the company's future performance.
- The vesting schedules for both the options and RSUs incentivize long-term commitment from the executive.
Future Outlook
The vesting schedules suggest a long-term commitment from the executive, aligning their interests with the company's future success.
Industry Context
Stock options and RSUs are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholder value.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron also utilize similar equity-based compensation to incentivize their executives.
- The vesting schedules and exercise prices are generally aligned with industry norms to ensure long-term commitment and performance.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align executive interests with long-term value creation.
- Employees may see this as a positive sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 04/04/2025 | Date of Earliest Transaction |
| 04/04/2025 | Stock Option grant date |
| 05/04/2025 | Stock Option monthly vesting begins |
| 03/02/2026 | RSU annual vesting begins |
| 04/04/2029 | Stock Option fully vested |
| 03/02/2029 | RSU grant date |
| 04/04/2035 | Stock Option expiration date |
| 04/08/2025 | Date of Form 4 signature |
Keywords
Form 4, Sutro Biopharma, Stock Options, Restricted Stock Units, RSUs, David Pauling, Beneficial Ownership, Equity Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.